Back to the article

HealthRX.com · Printable medication review sheet

Semaglutide product check: one molecule, several brands

List every semaglutide product you have been prescribed, with brand, form and strength, so two are never used at once by mistake. The FDA records below show Ozempic, Rybelsus and Wegovy are separate products approved for different uses.

Companion to “Wegovy History & Development: From GLP-1 Discovery to FDA Approval” · healthrx.com/wegovy/history-development · Facts checked 2026-10-19

Semaglutide products in FDA records

  • Ozempic injection (NDA 209637): approved December 5, 2017 for glycemic control in adults with type 2 diabetes.[1]
  • Rybelsus tablets (NDA 213051): approved September 20, 2019 for glycemic control in adults with type 2 diabetes.[2]
  • Wegovy injection (NDA 215256): approved June 4, 2021 for chronic weight management.[3]
  • Wegovy tablets (NDA 218316): approved December 22, 2025, on an application of their own.[4]
  • Ozempic tablets: from January 30, 2026, the name of the Rybelsus R2 formulation, on the Rybelsus application.[5]
  • The Wegovy Medication Guide says Wegovy should not be used with other semaglutide-containing products or other GLP-1 receptor agonist medicines.[6]

Every semaglutide product I have used

Brand and formStrengthPrescribed byStartedStoppedWhy it stopped

At every new prescription or refill

  • The brand and the form, injection or tablet, are the ones your prescriber named
  • No earlier semaglutide product is still on your active medication list
  • Leftover pens or tablets from an earlier product are set aside, not used alongside the new one
  • Your pharmacist has your full list of GLP-1 medicines, including any from another prescriber

For your prescriber or pharmacist

  1. Which semaglutide product am I on, and is my reason for treatment one of its approved uses?
  2. If I move to another semaglutide brand or form, at what dose do I start?
  3. What should I do with leftover pens or tablets from the product I am stopping?
  4. Was this product approved for my age group and condition, or is this use off-label?
Sources for the facts on this sheet
  1. U.S. Food and Drug Administration. Drugs@FDA: Ozempic (semaglutide) NDA 209637, approval history, letters, labels and reviews. Accessed 2026-10-19. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209637
  2. U.S. Food and Drug Administration. Drugs@FDA: Rybelsus and Ozempic (semaglutide) tablets, NDA 213051, approval history, letters, labels and reviews. Accessed 2026-10-19. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213051
  3. U.S. Food and Drug Administration. Drugs@FDA: Wegovy (semaglutide) injection NDA 215256, approval history, letters, labels and reviews. Accessed 2026-10-19. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215256
  4. U.S. Food and Drug Administration. Drugs@FDA: Wegovy (semaglutide) tablets NDA 218316, approval history, letters, labels and reviews. Accessed 2026-10-19. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218316
  5. U.S. Food and Drug Administration. NDA 213051/S-030 supplement approval letter for Ozempic (semaglutide) tablets and Rybelsus (semaglutide) tablets. Accessed 2026-10-19. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/213051Orig1s030ltr.pdf
  6. Novo Nordisk, via DailyMed. Wegovy (semaglutide) injection and tablets: prescribing information and Medication Guide. Effective 2026-06-18. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b

This sheet records information for a conversation with your prescriber or pharmacist. It does not replace their instructions or the medication's prescribing information.